Optimizing miltefosine treatment for leishmaniasis patients
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests how well miltefosine works for people with leishmaniasis, a skin infection from a parasite. It aims to find the best way to use this medicine to help patients get better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have leishmaniasis (confirmed by a lab test or skin sample).
- You must be older than 2 years old.
- Your doctor has decided to start treatment with miltefosine (a pill or liquid medicine).
- If you are a woman who can have children, you must agree to use birth control (like an IUD, implant, or shot) for 6 months.
- You must be willing to stay in the hospital for the whole treatment period.
- You must have normal blood test results (check with your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different drugs to find which works best for cutaneous leishmaniasis (a skin infection from a parasite). It may help people with many or large sores, or sores in sensitive areas like near the eyes or nose.
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
This study tests a gel form of miltefosine applied directly to skin sores caused by leishmaniasis. It is for adults with mild to moderate skin infections who have not already tried and failed other treatments.
This trial tests if oral medicines can treat cutaneous (skin) or mucosal leishmaniasis in people aged 60 and older. It compares two different pills to find a safer, easier option for elderly patients.
This trial tests a combination of two medicines—inhaled pentamidine and oral miltefosine—to treat mucosal leishmaniasis, a parasitic infection of the nose, mouth, and throat. It may be an option for people in Bolivia who have not been treated recently.
This study tests two new oral medicines compared to an existing oral medicine for people with a first episode of cutaneous leishmaniasis (skin sores caused by a parasite). It aims to find a more effective and convenient treatment.
Hear when a new Cutaneous Leishmaniases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.